September 27, 2024 07:11 AM EDTUpdated 08:04 AM

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

Ayisha Sharma

News Reporter

Cassava Sciences and two of its former executives have reached a resolution with the SEC over charges of “misleading” investors about the strength of data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

Ayisha Sharma

News Reporter

Sign up to read this article for free.

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

Travere halts Phase 3 inherited disease trial due to manufacturing scale-up issue

Exclusive: J&J folds cardiovascular and metabolic drug unit

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

Ayisha Sharma

News Reporter

Sign up to read this article for free.

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Steve Davis leaves Aca­dia, re­placed by Bris­tol My­ers alum; For­mer J&J ex­ec to lead R&D at No­vavax

Tra­vere halts Phase 3 in­her­it­ed dis­ease tri­al due to man­u­fac­tur­ing scale-up is­sue

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

Travere halts Phase 3 inherited disease trial due to manufacturing scale-up issue

Exclusive: J&J folds cardiovascular and metabolic drug unit

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships